

Special Issue

Bridging Pharmacoepidemiology and Pharmacoeconomics for Better Healthcare Outcomes

Message from the Guest Editor

The quality use of economic pharmacotherapy has always been a central topic in public health. Randomized controlled trials (RCTs) are the gold standard for drug effectiveness and safety research, whereas the characteristics of RCTs (such as a narrow group of participants, relatively short durations of therapies, and strict implementation of randomization) narrow their external validity when applying the trialed drugs in general populations with diverse characteristics and distinct utilization scenarios. Real-world evidence provides insights beyond those derived from RCTs in medical assessments and clinical practice decisions, along with innovative drug assessment approaches based on pharmacoepidemiology and pharmacoeconomics. Authors are welcome to submit original articles and systematic reviews on the effectiveness, safety, and economic burden of pharmacotherapies based on real-world data. Studies bridging pharmacoepidemiology and pharmacoeconomics are of particular interest to this Special Issue. We look forward to receiving your contributions.

Guest Editor

Dr. Hao Hu

Institute of Chinese Medical Sciences, University of Macau, Macao, China

Deadline for manuscript submissions

closed (31 May 2024)



Pharmacoepidemiology

an Open Access Journal
by MDPI



mdpi.com/si/186969

Pharmacoepidemiology
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





Pharmacoepidemiology

an Open Access Journal
by MDPI



[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Carlotta Franchi

Department of Health Policy, Head of Laboratory of
Pharmacoepidemiology and Human Nutrition, Istituto di Ricerche
Farmacologiche Mario Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 22.7 days after
submission; acceptance to publication is undertaken in 6.3
days (median values for papers published in this journal in
the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names published annually in the journal.